Work

Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide

Year: 2018

Type: article

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2018.11.021

Authors: Elie G. Dib, Emmanuel S. Antonarakis, Matthew J. Wasco, Steven F. Powell

Institutions: IHA Hematology Oncology Consultants, Sidney Kimmel Comprehensive Cancer Center, Sanford Health

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Vyriad, Bristol-Myers Squibb, Pfizer, AstraZeneca, Merck, Novartis, Sanofi, Clovis Oncology, Dendreon Pharmaceuticals, Genentech, Johnson and Johnson, Janssen Biotech

OpenAlex ID: W2904709685

FWCI: 0.188

Cites: 14

Cited by: 3

Related to: 10